Mission Wealth Management LP Invests $223,000 in Balchem Co. (NASDAQ:BCPC)

Mission Wealth Management LP acquired a new stake in Balchem Co. (NASDAQ:BCPC) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,496 shares of the basic materials company’s stock, valued at approximately $223,000.

A number of other institutional investors have also modified their holdings of the company. Signaturefd LLC grew its stake in Balchem by 123.0% during the fourth quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock worth $25,000 after buying an additional 91 shares during the period. Operose Advisors LLC acquired a new stake in Balchem in the 3rd quarter valued at $31,000. GAMMA Investing LLC acquired a new stake in Balchem in the 4th quarter valued at $56,000. Allworth Financial LP raised its position in Balchem by 17.8% in the fourth quarter. Allworth Financial LP now owns 953 shares of the basic materials company’s stock valued at $142,000 after purchasing an additional 144 shares during the period. Finally, Bill Few Associates Inc. acquired a new position in shares of Balchem during the fourth quarter worth about $212,000. Hedge funds and other institutional investors own 87.91% of the company’s stock.

Balchem Price Performance

Shares of BCPC stock opened at $150.40 on Friday. The firm has a fifty day simple moving average of $151.02 and a 200-day simple moving average of $140.58. The company has a market capitalization of $4.88 billion, a PE ratio of 44.90, a price-to-earnings-growth ratio of 3.19 and a beta of 0.72. Balchem Co. has a twelve month low of $110.74 and a twelve month high of $159.52. The company has a current ratio of 2.12, a quick ratio of 1.38 and a debt-to-equity ratio of 0.31.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings data on Friday, February 16th. The basic materials company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.02. Balchem had a net margin of 11.77% and a return on equity of 10.69%. The company had revenue of $228.70 million during the quarter, compared to analysts’ expectations of $234.66 million. During the same period in the prior year, the company posted $0.66 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. Equities research analysts anticipate that Balchem Co. will post 4.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Theodore L. Harris sold 34,350 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $154.29, for a total value of $5,299,861.50. Following the sale, the chief executive officer now directly owns 66,412 shares of the company’s stock, valued at $10,246,707.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Theodore L. Harris sold 34,350 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $154.29, for a total value of $5,299,861.50. Following the completion of the sale, the chief executive officer now directly owns 66,412 shares of the company’s stock, valued at $10,246,707.48. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Michael Robert Sestrick sold 11,100 shares of the stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $153.21, for a total value of $1,700,631.00. Following the transaction, the senior vice president now directly owns 6,736 shares in the company, valued at approximately $1,032,022.56. The disclosure for this sale can be found here. Insiders have sold 76,630 shares of company stock worth $11,843,249 in the last three months. 1.77% of the stock is owned by insiders.

Analyst Ratings Changes

Separately, StockNews.com downgraded Balchem from a “buy” rating to a “hold” rating in a report on Thursday, April 25th.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.